Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance)
- Citation:
- Annals of Oncology vol 28 (suppl_3) 153
- Meeting Instance:
- ESMO GI 2017
- Year:
- 2017
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, U10CA180790, U10CA180820, U10CA180835, U10CA180850, U10CA180863, U10CA180868, U10CA180888, CCSRI 021039, U24CA196067, U24CA196171
- Corr. Author:
- Authors:
- Frank A. Sinicrope Qian Shi Fabienne Hermitte Erica N. Heying Al B. Benson Sharlene Gill Richard M. Goldberg Morton S. Kahlenberg Suresh G. Nair Anthony F. Shields Daniel J. Sargent Jérôme Galon Steven R. Alberts
- Networks:
- Study
- NCCTG-N0147
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- immunologic adjuvants pharmaceutical adjuvants phase 3 clinical trials patient prognosis colon cancer fluorouracil/leucovorin calcium/oxaliplatin